Oxford Biomedica (LSE: OXB) is a leading, fully integrated, cell and gene therapy group.
We have built a sector leading viral vector platform, including our lentiviral vector delivery system, LentiVector® platform, which we leverage to develop in vivo and ex vivo products both in-house and with partners. We have also created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases.
Building on our world leading position in lentiviral vectors and success in the adenovirus vector-based AstraZeneca COVID-19 vaccine, we have demonstrated the versatility of our platform and have extended our scope to all types of viral vectors.
Oxford Biomedica has a number of further partnerships, including with Novartis, Juno Therapeutics/ Bristol Myers Squibb, Boehringer Ingelheim, Beam Therapeutics, Arcellx, Cabaletta, Orchard Therapeutics and Santen.
Additionally, we have a three-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine.
Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, Oxford Biomedica announced that it was broadening its leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business, Oxford Biomedica Solutions, based near Boston, Massachusetts, with Homology Medicines as a 20% owner.
Employees: 1-10
Founded date: 1995
Investors 1
Date | Name | Website |
- | Oxford Uni... | innovation... |
Mentions in press and media 9
Date | Title | Description | Source |
17.09.2020 | OXFORD BIOMEDICA PLC Oxford Biomedica : interim results for... | Oxford, UK - 17 September 2020: Oxford Biomedica plc ('Oxford Biomedica' or 'the Group') (LSE: OXB),... | marketscre... |
17.09.2020 | OXFORD BIOMEDICA PLC Oxford Biomedica : OXB Interim Results... | Page 1 of 29 OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2020 Oxford, U... | marketscre... |
26.06.2019 | Oxford Biomedica, Santen ink gene therapy pact; DayTw... | → British gene and cell therapy company Oxford Biomedica {LSE: $OXB} is joining forces with ... | endpts.com... |
30.05.2019 | Novo's investment arm injects $67.5M in Oxford Biomedi... | → The investment arm of Danish drugmaker Novo Nordisk $NVO is investing £53.5 million (abou... | endpts.com... |
13.03.2019 | Microsoft, Oxford Biomedica to apply cloud, machine learning... | Most gene therapies in development today rely on viral vectors, whereby a specially engineered virus... | medcitynew... |
06.07.2017 | Novartis turns to Oxford BioMedica for a major CAR-T s... | Oxford BioMedica has scored a major supply contract with Novartis for the lentiviral vecto... | endpts.com... |
30.11.2012 | Novel degenerative eye disease drug needs $2.5M to move into... | His next idea was that, rather than stopping the production of ATR, which would impede the vision cy... | medcitynew... |
- | Novel degenerative eye disease drug needs $2.5M to move into... | With an aging population and rising rates of vision loss, the U.S. pharmaceutical and medical device... | medcitynew... |
- | Microsoft, Oxford Biomedica to apply cloud, machine learning... | A British cell and gene therapy company is partnering up with the world’s largest software company t... | medcitynew... |